Latest news
Jazz Seeks FDA Withdrawal of Second-Line Lurbinectedin SCLC Indication - MedscapeMedscape · Fri, 07 Aug 2026 08:24:31 GMTSystImmune doses first patient in Phase III trial for ES-SCLC - Clinical Trials ArenaClinical Trials Arena · Thu, 06 Aug 2026 10:25:17 GMTDr Choudhury on Understanding Mechanisms of Resistance to DLL3-Directed BiTEs in SCLC - OncLiveOncLive · Wed, 05 Aug 2026 22:10:51 GMTLurbinectedin Second-Line SCLC Indication to Be Withdrawn After LAGOON - Targeted OncologyTargeted Oncology · Wed, 05 Aug 2026 14:09:27 GMTWithdrawal Planned for Second-Line Lurbinectedin in SCLC Indication - CancerNetworkCancerNetwork · Wed, 05 Aug 2026 14:09:23 GMTRecon: Lilly to broaden expanded access for unapproved obesity drug; Jazz to withdraw second-line SCLC indication for Zepzelca - RAPSRAPS · Tue, 04 Aug 2026 20:19:00 GMTProphylactic Cranial Irradiation Improves Survival in Limited-Stage SCLC - CancerNetworkCancerNetwork · Tue, 04 Aug 2026 15:08:44 GMTJazz to withdraw Zepzelca with FDA in second-line small cell lung cancer - Fierce PharmaFierce Pharma · Tue, 04 Aug 2026 13:18:16 GMT